Research programme: neuropsychiatric disorder therapeutics

Drug Profile

Research programme: neuropsychiatric disorder therapeutics

Alternative Names: IC 200131; ITI-333

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Analgesics; Antidepressants; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor modulators; Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Opioid mu receptor modulators; Serotonin 2A receptor antagonists; Serotonin receptor modulators; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders; Drug abuse; Pain
  • No development reported Mood disorders; Neurological disorders; Psychiatric disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Mood disorders in USA (PO)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top